RG 13022

Research use only, not for human use.

RG13022 is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM).

RG-13022 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 1 μM in HT-22 cells. Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs.

RG13022 suppresses EGF-stimulated cancer cell proliferation. In a cell-free reaction RG13022 inhibits the autophosphorylation reaction of the EGF receptor in immunoprecipitates with an IC50 of 4 μM. RG13022 inhibits colony formation and DNA synthesis by HER 14 cells, which were stimulated by 50 ng/mL EGF, in a dose-dependent manner. The IC50s are 1 and 3 μM for HER 14 colony formation and DNA synthesis, respectively. RG-13022 inhibits not only EGF-induced growth but also growth stimulated by insulin, insulin-like growth factor I, insulin-like growth factor II, or transforming growth factor alpha. RG-13022 also totally blocks estrogen-stimulated phosphorylation of the EGF receptor, as well as estrogen-induced cell proliferation, suggesting that functioning TK pathways are required for estrogen action.

RG13022 suppresses tumor growth in nude mice. RG13022 also increases the life span of these tumor-bearing nude mice.

RG 13022 | RG-13022.Tyrphostin RG 13022

Others

Other Targets

EGFR

——

——

136831-48-6

266.29

C16H14N2O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (375.53 mM)

COc1c(cc(cc1)/C=C(\C#N)/c1cnccc1)OC

3-Pyridineacetonitrile, alpha-((3,4-dimethoxyphenyl)methylene)-

(-20℃)

With Ice Pack

≥ 2 years